RECRUITING

Study of Intravenous ZMA001 in Healthy Subjects

Talk to us

Conditions

Pulmonary Arterial Hypertension PAHhuman monoclonal antibody (IgG1)

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Background: A number of diseases can cause a type of lung injury called pulmonary arterial hypertension (PAH). Most people who develop PAH do not survive more than a few years. A new study drug (ZMA001) may help. ZMA001 is a monoclonal antibody. This type of drug consists of proteins, made in a facility, that are very similar to proteins in a human body. But before giving ZMA001 to people sick with PAH, researchers want to find out how the drug affects healthy people. Objective: To test a drug (ZMA001) in healthy volunteers. Eligibility: Healthy adults aged 18 to 60 years. Design: Participants will be screened. They will have a physical exam with blood tests. They will have a urine test for drug use. They will have a test of their heart function. Participants will come to the clinic for 1 inpatient visit of up to 48 hours. ZMA001 is a liquid administered through a tube attached to a needle inserted into a vein in the arm. Participants will receive this drug only once, during their inpatient stay. Some participants will receive the drug; others will receive a placebo in Cohort 1 only. A placebo is a treatment that looks just like the real drug but contains no medicine. Participants will not know which treatment they are getting in Cohort 1. Cohorts 2-4 will receive a single dose of the study drug, administered through a tube attached to a needle inserted into a vein in the arm. After a screening visit, participants will have 1 inpatient visit and up to 8 outpatient visits over 16 weeks after receiving the treatment. Blood draws and other tests will be repeated. Each outpatient visit is approximately 2 hours long. This study is the first time ZMA001 will be administered to people.

Official Title

A Phase 1 Single-Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous ZMA001 in Healthy Subjects

Quick Facts

Study Start:2023-11-27
Study Completion:2027-11-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05967299

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 60 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Stated willingness to comply with all study procedures and availability for the duration of the study
  2. 2. Male\* or female, aged 18 to 60 years, inclusive
  3. 3. In good general health as evidenced by medical history
  4. 4. Females of childbearing potential agree to use an accepted method of contraception (see below) throughout study participation and for 120 days after study drug infusion.
  5. 5. Males sexually active with a female partner must agree to use a condom with spermicide for 120 days after study drug infusion or be surgically sterile for at least 90 days before screening. Males must also agree to not donate sperm for 120 days after study drug administration.
  6. 6. Agreement to adhere to Lifestyle Considerations throughout study duration
  7. 7. Ability of subject to understand and the willingness to sign a written informed consent document.
  8. * Enrollment of healthy male subjects will be limited to no more than 14 out of the total study cohort of 32 in order to ensure an adequate representation of female subjects.
  9. * Use of an implanted or intrauterine hormonal device for at least 30 consecutive days before study drug infusion
  10. * Use of oral, patch or injectable contraceptives or a vaginal hormonal device for at least 30 consecutive days before study drug infusion
  11. * Use of a non-hormonal intrauterine device for at least 30 consecutive days before study drug infusion
  12. * Two barrier methods such as a diaphragm with spermicide or a condom with spermicide
  1. 1. Pregnancy or lactation. Females of childbearing potential must have a negative serum Beta-human chorionic gonadotropin test no more than 48 hours from study drug infusion.
  2. 2. A history of human immunodeficiency virus (HIV) infection.
  3. 3. History of severe drug or excipient allergy or hypersensitivity
  4. 4. Known allergy to any of the components of the investigational drug or placebo
  5. 5. Recent infection or febrile illness within the past 14 days
  6. 6. Treatment with another investigational drug within the past 30 days or 5 half-lives, whichever is longer
  7. 7. Any vaccination within the past 4 weeks or receipt of a live-attenuated vaccine within the past 6 months
  8. 8. Use of tobacco products within the past 3 months
  9. 9. Recreational drug use within the past 6 months or positive urine drug screen at Screening Visit
  10. 10. History of alcohol abuse within the past 2 years
  11. 11. Current clinically significant medical illness that is uncontrolled despite appropriate medical treatment including (but not limited to) hematologic, oncologic, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, infectious, hepatic, dermatologic, psychiatric, neurologic, autoimmune or allergic disease
  12. 12. Body mass index less than 17 or greater than 32 kg/m\^2
  13. 13. Clinically significant abnormal results on clinical blood testing completed at the Screening Visit
  14. 14. Electrocardiographic evidence of clinically relevant heart disease
  15. 15. Diabetes mellitus requiring medical treatment
  16. 16. Received another monoclonal antibody in the past 30 days
  17. 17. Use of herbal supplements, or similar products within the past 2 weeks
  18. 18. Blood donation equal to or above 500 mL within 2 months prior to dosing.
  19. 19. Any other finding that, in the judgment of the Investigator, would increase the risk of having an adverse outcome from participating in the study.

Contacts and Locations

Study Contact

Sandra Cooper Bennett, R.N.
CONTACT
(240) 328-0465
sandra.cooper@nih.gov
Jason M Elinoff, M.D.
CONTACT
(301) 978-6468
elinoffj@mail.nih.gov

Principal Investigator

Jason M Elinoff, M.D.
PRINCIPAL_INVESTIGATOR
National Heart, Lung, and Blood Institute (NHLBI)

Study Locations (Sites)

National Institutes of Health Clinical Center
Bethesda, Maryland, 20892
United States

Collaborators and Investigators

Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

  • Jason M Elinoff, M.D., PRINCIPAL_INVESTIGATOR, National Heart, Lung, and Blood Institute (NHLBI)

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-11-27
Study Completion Date2027-11-30

Study Record Updates

Study Start Date2023-11-27
Study Completion Date2027-11-30

Terms related to this study

Keywords Provided by Researchers

  • human monoclonal antibody (IgG1)

Additional Relevant MeSH Terms

  • Pulmonary Arterial Hypertension PAH